Wolfson Institute of Preventive Medicine

Search - ZOO
Search - K2
Search - Categories
Search - Contacts
Search - Content
Search - Newsfeeds
Search - Weblinks

Benefits and Harms of aspirin in the general population

In a paper published in the Annals of Oncology, a team of scientists has reviewed all the available evidence from many studies and clinical trials assessing both the benefits and the harms of preventive use of aspirin. This team of international experts was led by Prof. Jack Cuzick, Director, Wolfson Institute of Preventive Medicine and also included two other scientists from the Wolfson Institute of Preventive Medicine; Dr. Mangesh Thorat from the Centre for Cancer Prevention and Prof. Malcolm Law from the Centre for Environmental and Preventive Medicine.

This is the first study to consider all diseases aspirin affects and comprehensively assess overall benefits and harms of aspirin at a general population level. The study found that prophylactic aspirin use for a minimum of 5 years at doses between 75 and 325 mg/day has a favourable benefit–harm profile for average-risk individuals aged 50 to 65 years. The study has been very widely received in electronic and print media.

For the full paper please click here or to read the press release from Prof. Jack Cuzick follow this link
QMUL Media Coverage

Return to top